SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today ...

SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today ...

EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK 12.03.2025 / 14:06 CET/CEST The issuer is solely responsible for ...

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two ...

Compugen's pipeline, including COM701 and COM503, aims to transform tumor responsiveness through unique immunotherapy strategies, potentially reshaping the immuno-oncology landscape. Despite ...

Ellipses has agreed to in-license global rights to ‘GENA-104’, a first-in-class immuno-oncology monoclonal antibody that targets CNTN4, a recently discovered checkpoint protein that is highly ...

Incyte has formally terminated its yearslong partnership with Agenus, giving the Massachusetts-based biotech all rights over certain immuno-oncology programs. The decision, which Agenus announced in ...

Incyte has broken off its immuno-oncology deal with Agenus. The step, which follows a series of program terminations, will give Agenus full control of assets that it will consider advancing ...